Nestle outmuscles Danone for Pfizer’s nutrition biz

Swiss food giant Nestle beats Danone for the control of Pfizer’s infant nutrition business. This $11.9 billion cash deal allows Nestle to expand its footprint in the global baby food market, while Pfizer could now focus on its core drug-making business. The baby infant nutrition business has been a growing segment in the healthy food category, with the emerging markets contributing most of the growth.

Read more on Dealbook.

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.